April 30, 2021
A phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients with Advanced Sarcomas
TYPE OF SARCOMA: Undifferentiated Pleomorphic Sarcoma and Poorly Differentiated/Dedifferentiated Liposarcoma
DRUG: Pembrolizumab
ACCRUAL STATUS: Not Recruiting
OVERALL STUDY PRINCIPAL INVESTIGATOR:
Hussein Tawbi, MD, PhD
Associate Professor of Medicine
The University of Texas MD Anderson Cancer Center
FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV
CLINICALTRIALS.GOV IDENTIFIER: NCT02301039
To learn more about this study or to contact the study research staff: